Liver Cancer Trial, Recruiting (NCT07186010)

Liver Cancer Trial, Recruiting NCT07186010 Sponsor: Asan Medical Center Condition: Liver Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT07186010 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Liver Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with liver cancer (called HCC) confirmed by a tissue sample test
People whose liver cancer has spread, come back, or cannot be removed, and where surgery, liver transplant, or a heat-based tumour treatment (radiofrequency ablation) have been ruled out as options
People who are planned to receive a type of cancer treatment that works with the immune system

Who may not be able to join:

People whose liver cancer has been identified as a specific rare type, including fibrolamellar HCC, sarcomatoid HCC, or a mixed form involving bile duct cancer (confirm with trial site if unsure which type applies)
People who currently have another type of cancer at the same time
People who are considered suitable candidates for surgery to remove part of the liver, a liver transplant, or radiofrequency ablation
People whose participation might make the trial results difficult to interpret or unreliable (confirm with trial site for specifics)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ju Hyun Shim, Asan Medical Center

Phone: 0230103190

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07186010

Sponsor: Asan Medical Center

Phase: Not Applicable

Status: Recruiting

Condition: Liver Cancer

Trial contact: 0230103190

More information: https://clinicaltrials.gov/study/NCT07186010

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with liver cancer (called HCC) confirmed by a tissue sample test
People whose liver cancer has spread, come back, or cannot be removed, and where surgery, liver transplant, or a heat-based tumour treatment (radiofrequency ablation) have been ruled out as options
People who are planned to receive a type of cancer treatment that works with the immune system

Who may not be able to join:

People whose liver cancer has been identified as a specific rare type, including fibrolamellar HCC, sarcomatoid HCC, or a mixed form involving bile duct cancer (confirm with trial site if unsure which type applies)
People who currently have another type of cancer at the same time
People who are considered suitable candidates for surgery to remove part of the liver, a liver transplant, or radiofrequency ablation
People whose participation might make the trial results difficult to interpret or unreliable (confirm with trial site for specifics)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Asan Medical Center

Registry

ClinicalTrials.gov

Start date

28 September 2020

Est. completion

31 December 2026

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Objective response rate (ORR) according to RECIST 1.1 criteria

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov